News

Video

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

Author(s):

Ulka Vaishampayan, MDAlan Tan, MD

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

Related Videos
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Naval G. Daver, MD
Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Elias Jabbour, MD,
Ibrahim T. Aldoss, MD
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Shubham Pant, MD, MBBS
Related Content
Michelle Mendoza, PhD, of Huntsman Cancer Institute
July 26th 2024

Mendoza, Weiss Receive $2.6 Million Grant to Study Biomechanics of Lung Tumors

Robert Z. Orlowski, MD, PhD, Florence Maude Thomas Cancer Research Professorship, Department of Lymphoma/Myeloma, director, Section of Myeloma, professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
July 11th 2024

Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

Jennifer Doherty, PhD, MS
July 23rd 2024

Landmark Study Shows Elevated Cancer Risk For Women With Endometriosis

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Michael Wang, MD, professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
July 18th 2024

Ibrutinib Plus Venetoclax Generates Durable CRs in TP53+ Mantle Cell Lymphoma

Guillermo Garcia-Manero, MD
July 17th 2024

Real-World and Post-Hoc Analyses Support Luspatercept Use in Low-Risk Myelodysplastic Syndrome